Anchored on the first FDA-licensed freeze-dried plasma product, expanded to the full evidence base: permissive hypotension, blood product ratios, prehospital plasma's genuinely contradictory trial record, and why fluid choice itself is context-dependent. Verified against FDA.gov, NEJM, Lancet Haematology, JAMA Surgery, and primary damage-control-resuscitation literature. July 2026.
On July 29, 2026, the FDA licensed Ezplaz Freeze Dried Plasma (Vascular Solutions, LLC, a Teleflex subsidiary) — the first freeze-dried plasma product licensed for use in the United States.
| Feature | Detail |
|---|---|
| Composition | Lyophilized (freeze-dried) plasma derived from a single unit of fresh frozen plasma, FDA-licensed blood establishments |
| Storage | Room-temperature stable, tolerates temperature fluctuation — no cold chain or thaw cycle required |
| Reconstitution | Rapid, roughly one minute, using included sterile water |
| Blood types available | Group AB and Group A with low-titer anti-B — chosen specifically to reduce risk when transfused before the recipient's blood type is known |
| Packaging | Plastic bag rather than glass bottle, reducing breakage risk in transport |
| Licensed indication | Adults who require plasma when other plasma products are not available — active bleeding, massive transfusion, certain bleeding patients on warfarin |
One correction to the common framing: the AB/A-low-titer-anti-B selection is about donor-to-recipient compatibility without knowing the recipient's type — it doesn't mean the product is given without any regard to ABO status, it means it's selected to be safe across the recipient types most likely to be encountered emergently.
A room-temperature plasma product is a genuine logistics advance. But "maintaining volemic status" in hemorrhagic shock is a much larger question than which plasma product to stock — it spans whether to give fluid at all before bleeding is controlled, what ratio of blood components to use, whether prehospital blood products actually improve survival, and even which crystalloid to reach for when blood products aren't available. Each of those has genuine, sometimes contradictory, randomized trial evidence behind it.
Bickell et al., NEJM 1994 — the foundational trial: 598 adults with penetrating torso trauma and prehospital SBP ≤90 mmHg, randomized to immediate prehospital/ED fluid resuscitation vs. delayed resuscitation withheld until operative control. Survival to discharge was significantly higher in the delayed group (70% vs. 62%, p=0.04).
The theory: aggressive crystalloid before hemorrhage control raises blood pressure enough to dislodge a forming clot ("popping the clot"), while also driving dilutional coagulopathy, dilutional anemia, and hypothermia — the same lethal triad damage control resuscitation is built to avoid.
| Real limitations of the founding trial | Why it matters |
|---|---|
| Single center, single EMS system, penetrating torso trauma only | Limited external validity to blunt trauma or systems with different transport times |
| Used crystalloid, not modern hemostatic/blood-component resuscitation | The comparison being tested has moved on since 1994 — the trial predates the blood-ratio evidence in section 4 |
| Blood pressure was actually similar between groups regardless of allocation | A frequently overlooked methodologic detail — raises the question of what, mechanistically, actually drove the mortality difference |
Current practice generally applies permissive hypotension (targeting SBP ~80–90 mmHg or MAP ~50 in pure hemorrhagic shock per EAST guidance) until hemorrhage is controlled — with an important carve-out for concurrent traumatic brain injury, where SBP <90 is independently associated with worse outcomes and small aliquots (100–200 mL) to maintain SBP above 90 are favored instead.
PROPPR (Holcomb et al., JAMA 2015): in-hospital massive transfusion trial comparing plasma:platelets:RBC ratios of 1:1:1 vs. 1:1:2. No statistically significant difference in 24-hour or 30-day mortality between ratios, though more patients in the 1:1:1 group achieved hemostasis and fewer died from exsanguination in the first 24 hours.
Despite PROPPR not reaching significance on its primary mortality endpoint, balanced-ratio transfusion (approximating whole blood composition) has been widely adopted as practice — built substantially on observational data with real survivorship-bias risk (patients have to survive long enough to receive the later components of a ratio). A smaller earlier RCT (Nascimento 2013) comparing a 1:1:1 target to standard care actually found higher, though not statistically significant, mortality in the balanced-ratio group — a reminder that the observational enthusiasm for balanced ratios outran the randomized evidence for some time.
This is the section most relevant to evaluating EZPLAZ's real-world promise, and it's considerably messier than "prehospital plasma saves lives."
| Trial | Design | Result |
|---|---|---|
| PAMPer (NEJM 2018) | Cluster-randomized, air-medical transport, 2 units thawed plasma vs. standard care | Positive — reduced 30-day mortality with prehospital plasma |
| COMBAT (2018) | 2 units thawed AB plasma prehospital vs. standard crystalloid care, ground EMS | Negative — stopped early for futility; no outcome difference; groups imbalanced at baseline (plasma arm sicker) |
| RePHILL (Lancet Haematology 2022) | UK phase 3 RCT, PRBC + lyophilized plasma vs. saline, prehospital | Negative — did not demonstrate improved survival or lactate clearance; stopped early (COVID-19 disruption) |
Worth sitting with: RePHILL is the trial that actually tested lyophilized plasma — the same category of product EZPLAZ belongs to — in the prehospital setting, and it was negative on both primary outcomes. This doesn't mean EZPLAZ won't help; RePHILL tested a different lyophilized product (Lyoplas) in a different health system with its own transport times, and was underpowered by early stopping. But it's a directly relevant data point that a clean "freeze-dried plasma saves lives" framing skips entirely.
A post hoc analysis pooling PAMPer and COMBAT found the prehospital plasma survival benefit was concentrated in patients with transport times longer than 20 minutes — suggesting the effect, where real, may be distance/time-dependent rather than universal. That's directly relevant to EZPLAZ's marketed use case (rural, combat, disaster settings with inherently longer transport times) — plausibly the population most likely to benefit, though not yet tested with this specific product. PREHO-PLYO (France, 2022, 134 patients) tested lyophilized plasma against saline and found no difference in admission INR (1.21 vs 1.20).
When blood products aren't available or aren't yet indicated, the choice of crystalloid itself isn't a one-size-fits-all answer — a network meta-analysis across sepsis, surgical, and trauma populations found the "best" fluid actually flips depending on the clinical context.
| Population | Finding |
|---|---|
| Sepsis | Balanced crystalloids reduced mortality more than saline (OR 0.84) and more than hydroxyethyl starch (OR 0.81), and reduced AKI more than starch — though balanced crystalloids required the largest resuscitation volume of any fluid type. |
| Traumatic brain injury specifically | Saline and hydroxyethyl starch achieved lower mortality than albumin and balanced crystalloids — saline was significantly superior to albumin (OR 0.55). The opposite direction from the sepsis finding. |
The practical implication: "always use balanced crystalloid" is a reasonable sepsis-driven default that doesn't automatically transfer to trauma, and specifically doesn't transfer to TBI, where the osmotic properties of saline may matter more than the acid-base-friendly profile of a balanced solution. Fluid choice, like blood product ratio, is a population-specific question, not a universal one.
This isn't a new concept globally — the US is late to it. Lyophilized plasma has been used by the French military since the 1990s and has been part of NATO-allied combat casualty care doctrine for years; EZPLAZ is the first product to carry a US biologics license for this category, not the first freeze-dried plasma product to exist or see operational use anywhere.
| Advantage over frozen plasma | Advantage over whole blood |
|---|---|
| No cold chain, no thaw cycle, longer effective shelf stability | No refrigeration requirement at all; lower risk of a hemolytic transfusion reaction from ABO mismatch since it's plasma-only, not whole blood |
| Plastic packaging reduces breakage in transport/combat/disaster movement | Doesn't require the donor screening/logistics infrastructure of a walking blood bank or prehospital whole blood program |
What freeze-dried plasma doesn't solve: it's still plasma alone, not a red-cell-carrying product — it doesn't restore oxygen-carrying capacity the way PRBCs or whole blood do. In a patient who needs volume and oxygen-carrying capacity, freeze-dried plasma is one component of resuscitation, not a complete substitute for red cells when they're available.
What's well-supported: permissive hypotension until hemorrhage control (outside TBI), balanced blood-component resuscitation over crystalloid-heavy strategies once blood products are available, and matching crystalloid choice to the clinical context rather than defaulting to one fluid for every population.
What's still genuinely unsettled: whether prehospital plasma of any kind (frozen or freeze-dried) reliably improves survival across all transport-time and injury profiles — PAMPer says yes, COMBAT and RePHILL say no, and the honest read is that the benefit may be real but concentrated in longer-transport, resource-limited settings exactly like the ones EZPLAZ is marketed toward. That's a plausible hypothesis, not yet a demonstrated result for this specific product.
EZPLAZ is a genuine logistics advance for austere and prolonged-field-care settings — the room-temperature stability and reduced breakage risk solve real, practical problems frozen plasma has always had. Whether it moves a survival needle in the field is a question the existing lyophilized-plasma trial evidence (RePHILL, negative) hasn't yet answered in this product's favor, and the ongoing trials mentioned in section 5 are the ones actually positioned to answer it.
| Question | Current answer |
|---|---|
| Fluid before hemorrhage control? | Permissive hypotension (SBP ~80–90) outside TBI; small aliquots to SBP >90 if TBI present |
| Blood component ratio once available? | Balanced (~1:1:1) widely adopted; PROPPR itself didn't reach significance on mortality |
| Does prehospital plasma improve survival? | Contradictory — positive (PAMPer), negative (COMBAT), negative for lyophilized specifically (RePHILL); likely concentrated in long-transport settings |
| Which crystalloid, if no blood available? | Balanced solutions favored in sepsis; saline/starch outperform balanced solutions and albumin in TBI specifically |
| Does EZPLAZ solve the oxygen-carrying problem too? | No — it's plasma only; doesn't replace PRBCs or whole blood when red-cell capacity is needed |
Primary sources checked for this guide: